Am J Transplant, Volume 18, Suppl 3 Archives - Page 18 of 211 - ATC Abstracts

2018 American Transplant Congress
An Early Look at the OPTN's New SLK Allocation Policy
A. Kucheryavaya,¹ R. Formica,² N. Turgeon,³ D. Stewart,¹ A. Wilk.¹
¹UNOS, Richmond; ²Yale School of Medicine, New Haven; ³Emory Univ Hosp, Atlanta.
Background: The new Simultaneous Liver-Kidney (SLK) allocation policy went into effect on 8/10/17. It established renal medical criteria for patients waiting for SLK transplants and…
2018 American Transplant Congress
Urine AngiotensinII Signature Proteins as Biomarkers of Fibrosis in Kidney Transplant Recipients
Z. Mohammed-Ali,¹ S. Reid,^1,3 T. Tokar,¹ A. Tavares,² P. Yip,¹ H. Cardinal,² Y. Li,¹ S. Kim,^1,3 I. Jurisica,^1,3 R. John,¹ A. Konvalinka.^1,3
¹University Health Network, Toronto, ON, Canada; ²Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; ³University of Toronto, Toronto, ON, Canada.
AngiotensinII (AngII), the main effector of the renin-angiotensin system (RAS), causes kidney interstitial fibrosis/tubular atrophy (IFTA). However, there are presently no markers of AngII renal…
2018 American Transplant Congress
Immune Phenotyping in a Pediatric Multicenter Transplant Study: Suitability of a Pre-Formulated Dry Antibody Panel System
S. Urschel,¹ L. Ionescu,¹ T. Blydt-Hansen,³ B. Foster,⁵ S. Mital,² U. Allan,² S. Iveson,³ L. Hamiwka,⁴ J. Yap,¹ V. Phan,⁵ P. Birk,⁶ L. West,¹ M. Levings.³
¹U of Alberta, Edmonton, Canada; ²Sickkids, Toronto, Canada; ³U of BC, Vancouver, Canada; ⁴U of Calgary, Calgary, Canada; ⁵Montreal Children's, Montreal, Canada; ⁶U Manitoba, Winnipeg, Canada.
Background:Flow cytometric immune-phenotyping is influenced by cryopreservation and inter-laboratory variability limiting comparability in multi center studies. The Duraclone™ system (DC) provides optimized pre-mixed dry antibody…
2018 American Transplant Congress
Ischemia Reperfusion Injury Significantly Differs between Lung vs. Heart Transplantation with Respect to Lead Cytokines and Correlation to Clinical Outcome
B. Wiegmann,¹ N. Ledwoch,² J. ISke,² C. Neudörfl,² I. Tudorache,¹ C. Kühn,¹ T. Kaufeld,¹ F. Ius,¹ S. Rojas,¹ M. Avsar,¹ A. Haverich,¹ G. Warnwcke,¹ C. Falk.¹
¹Department of Cardiothoracic Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany.
ObjectivesIschemia reperfusion injury (IRI) is known to impair early graft function after lung (LTx) or heart (HTx) transplantation. We have previously characterized IRI in lungs…
2018 American Transplant Congress
Absolute Quantification of Plasma Graft-Derived Cell-Free DNA for Diagnosis of Kidney Transplant Rejection
J. Whitlam,¹ L. Ling,² F. Ierino,³ D. Bruno,² H. Slater,² D. Power.¹
¹Austin Health, Heidelberg, Victoria, Australia; ²Murdoch Childrens Research Institute, Parkville, Victoria, Australia; ³St Vincent's Health, Fitzroy, Victoria, Australia.
Aim: To study the performance of droplet digital PCR absolute measurement of graft-derived cell-free DNA (gdcfDNA) for the diagnosis of kidney allograft rejection.Methods: Homozygous deletion…
2018 American Transplant Congress
Double Deficiency of Gelatinase-A and Gelatinase-B Does Not Protect against Hepatic Ischemia Reperfusion Injury
S. Duarte, P. Matian, S. Ma, R. Busuttil, A. Coito.
Dumont-UCLA Transplant Center, Los Angeles.
Gelatinases, consisting of gelatinase A (MMP-2; 72 KDa) and gelatinase B (MMP-9; 92KDa), are a subgroup of matrix metalloproteinases (MMPs) with key roles in a…
2018 American Transplant Congress
Diagnosis of Antibody-Mediated Rejection after Kidney Transplantation by Blood Expression of Genes Involved in IFN Signaling
M. Matz,¹ Q. Zhang,¹ F. Heinrich,² C. Lorkowski,¹ K. Wu,³ P. Durek,² N. Lachmann,⁴ M-.F. Mashreghi,² K. Budde.¹
¹Nephrology, University Medicine Charité Berlin, Berlin, Germany; ²Drfz, Berlin, Germany; ³Pathology, University Medicine Charité Berlin, Berlin, Germany; ⁴Center For Tumor Medicine, H&I Laboratory, University Medicine Charité Berlin, Berlin, Germany.
Purpose: Antibody-mediated rejection (ABMR) has been recognized as a major cause of graft loss. Early diagnosis and effective treatment are crucial for salvaging grafts undergoing…
2018 American Transplant Congress
C1q-Binding Donor-Specific Anti-HLA Antibodies for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard of Care Treatment
C. Lefaucheur,¹ D. Viglietti,¹ Y. Bouatou,¹ O. Aubert,¹ A. Zeevi,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Pittsburgh Medical Center, Pittsburgh.
One of the major issues in the clinical management of kidney recipients with ABMR is the lack of early and reliable markers that surrogate long-term…
2018 American Transplant Congress
Biopsy Correlates of DSA in Antibody-Mediated Rejection: C4d vs Microvascular Inflammation Scores
C. Harris, L. Anderson, R. Khaim, J. Choudhuri, R. Shapiro, S. Florman, F. Salem, M. Menon.
Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The diagnosis of antibody-mediated rejection (AMR) requires the presence of both the histologic features of AMR as well as donor-specific antibodies (DSA). Whether anti-HLA…
2018 American Transplant Congress
Magnitude of Pre-Biopsy Decline in Renal Function and Its Association with Allograft Rejection
S. Voora,¹ P. Ahearn,¹ M. Tavakol,² K. Johansen,^1,3 E. Ku.¹
¹Division of Nephrology, UCSF, San Francisco, CA; ²Department of Surgery, UCSF, San Francisco, CA; ³Department of Epidemiology/Biostatistics, UCSF, San Francisco, CA.
Introduction: Acute rejection is a significant cause of morbidity, and transplant biopsy remains the gold standard for diagnosing rejection. To our knowledge there have been…